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1. Introduction
Malignant pleural mesothelioma (MPM) is a primary malignancy of the pleura. The main
aetiological agent is asbestos. The latency period lasts several decades, and in countries where
its use was banned in the 1950’s and 1960’s, the incidence is expected to peak within the coming
decade. However, in the many other countries it continues to be mined and used. The incidence
in these countries can be expected to continue to rise.
The prognosis for MPM is dismal and the median survival from the time of diagnosis is 12 to
18 months. Current therapies are blunt weapons that are very morbid but at the same time
ineffective. They have barely made an impact on the poor outcomes of mesothelioma.
In this chapter, we will review the current knowledge on mesothelioma pathogenesis,
epidemiology, biology and treatment. We will focus on nonoperative therapies and the role
of surgery will be covered in another chapter.
2. Epidemiology and aetiological factors
2.1. The history of asbestos and mesothelioma
Following the earliest descriptions of mesothelioma, it remained an exceptionally rare
malignancy until after industrialisation. For a long time, primary pleural malignancies were
so rare that their very existence was disputed [1]. In the early 1950s, a number of reports noted
small clusters of MPM but it was not until the late 1950s in South Africa when Kit Sleggs noted
that patients with tuberculous pleurisy from the east of Kimberly were recovering with
streptomycin and isoniazid, but a number of patients apparently with the same disease from
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the west of Kimberly continued to die. The pathologist Christopher Wagner observed that
these patients had in fact a rare cancer of the pleura but yet without any other primary tumours,
leading to the conclusion they had primary mesothelioma. In the same period, there were no
mesotheliomas observed amongst 10,000 lungs examined from other areas of South Africa.
This begged the question of why they were diagnosing so many of these rare tumours in west
Kimberly. Wagner observed asbestos bodies in the lung beneath the tumour and surmised
their association with mesothelioma, from that moment on the link was made [2]. His publi‐
cation “Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape
Province” became the most cited paper in industrial medicine. This started a lifelong investi‐
gation into the association of MPM with asbestos [3].
Asbestos is a family of long, thin, fibrinous, hydrated magnesium-silicate crystals. The first
record of its human use is from over 5,000 years ago, and Persians were known to make cloth
with it that could be cleansed by throwing it into the fire [4]. They are classified according to
their morphology into the straight and rod-like amphiboles, and the curly serpentines fibres.
The amphiboles, which include crocidolite, amosite and tremolite, are strongly associated with
the development of mesothelioma. The serpentine fibre chrysotile, believed to be less carci‐
nogenic by some and non-carcinogenic by others, continues to be mined and sold in Canada
to this day. The carcinogenicity of different asbestos preparations is also related to the fibre
dimensions, with long, thin fibres being most strongly carcinogenic [5].
Asbestos is a versatile material valued for being weavable, resistant to heat, electricity and
chemicals, being readily available and cheap. It is used in the building and construction,
machinery, shipbuilding and transport industries, hence asbestos-related diseases including
mesothelioma are mainly industrial work-related and therefore more common in males. The
main cohorts with exposure are occupational - those working directly with the mining and
preparation of asbestos (eg. mixing asbestos cement, cutting sheets, lagging) and end-users of
asbestos such as builders, plumbers and shipyard workers, paraoccupational - in people living
with people working with asbestos and environmental - from exposure to naturally occurring
asbestos.
The background incidence of mesothelioma is approximately 1 per million, rising to 7 per
million in Japan, 12 per million in the United States, 33 per million in the United Kingdom and
40 per million in Australia in a pattern consistent with the distribution of asbestos exposure.
In Wittenoon, Western Australia where crocidolite was mined in the 1930s, follow-up records
of 6,493 employees found MPM caused 3.4% deaths in exposed male workers [6]. The predicted
peak incidence is expected to occur between 2005 and 2025 in countries which banned its use
[7]. It is more common in males, and with a latency period between three and four decades [8],
the median age at diagnosis is in the sixth and seventh decades, although there are instances
when it can present in the second decade, often with a history of perinatal exposure.
There is an exposure dose-response relationship between asbestos and mesothelioma, both in
terms of historic exposure (duration and episodes) and lung asbestos fibre content [9], [10] [11].
The risk is highest with crocidolite and amosite, and less with chrysotile. However, there is a
background rate of mesothelioma, and virtually all mankind has been exposed to asbestos at
some point – fibres have been found in the lungs of the general population. Because of this, it
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has not been possible to determine a threshold level below which exposure could be deemed
safe [12] and this has important implications for legislation.
As of August 2012, 54 countries have banned the use of all types of asbestos [13]. For the rest of
the countries, nearly all of the asbestos mined and consumed today is chrysotile asbestos.
Developing countries are the highest consumers of asbestos, with China topping the list. With
its rapid growth, China’s production could not keep pace with its insatiable domestic appetite
and needs to import a quarter of its asbestos. Russia, the world’s largest producer with re‐
serves that will last over a century, exports most of its asbestos [14]. Whilst the European Union
and United States have complete bans on asbestos, Canada continues to mine chrysotile asbestos
and is the fifth largest exporter of chrysotile to developing countries. This is in spite of severe
restrictions on its domestic use. Although international agencies have long condemned the use
of asbestos, it has been difficult to come to an agreement for an international ban. In June 2011,
Canada for a third time objected to the inclusion of chrysotile asbestos under Annex III of the
Rotterdam Convention.
2.2. The chrysotile controversy
The carcinogenicity of the amphiboles is now indisputable, but for chrysotile this has been fiercely
debated. Most of the asbestos mined and utilised today is chrysotile, on the belief that this fibre
is safe. This assumption is based on studies showing lesser biopersistence of the fibres, which is
likely the result of the fibre’s fragility, leading to fragmentation and quicker clearance from the
lungs.  Epidemiological  studies  which  suggest  chrysotile  causes  mesothelioma were  dis‐
missed by blaming contamination by amphiboles – the so-called ‘Amphibole hypothesis’ [15].
The experimental methodologies behind these studies have been questioned [16] [17] and it has
become clear that even though chrysotile may be less potent at inducing mesothelioma, the
heightened risks of asbestosis, lung cancer and death is still a glaring reality [18, 19].
2.3. Other implicated aetiological factors
2.3.1. Erionite and genetic susceptibility
An epidemic of malignant mesothelioma unfolded in 3 villages in Cappadocia, Turkey in the
1980’s accounting for an unprecedented 50% of deaths in the region. In comparison to
unaffected neighbouring villages, villages with mesothelioma also had high levels of airborne
erionite, a fibrous zeolite with some similarities to asbestos [20]. Certainly, in animal models
erionite is a very potent inducer of mesothelioma [21]. However, the incidence of mesothelioma
in a nearby village with similar erionite levels was significantly lower, implicating other factors
at play. Lineage studies have since incriminated an autosomal dominant transmission of
susceptibility to fibre carcinogenesis to explain the disparity [22], but exposure to erionite itself
remains the dominant driver of carcinogenesis [23].
Whilst erionite is also present in other parts of the world, mesothelioma directly attributable to
erionite is still very rare [24]. Nevertheless, with a long latency period over three decades, the
possibility of a future epidemic in erionite-rich areas, such as parts of America, is a concern [25].
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2.3.2. SV40
SV40 is a polyoma virus which has long been studied as a carcinogen. The concerns over SV40
arose from the widespread administration of SV40-contaminated polio vaccines which were
distributed worldwide in the 1960’s. Certainly in the laboratory, SV40 virus has the ability to
transform human cells and induce mesothelioma in experimental animals both directly, and
as a co-carcinogen acting synergistically with asbestos [26] [27]. However, its relevance to
clinical mesothelioma is less clear and the evidence is largely circumstantial. SV40 DNA
fragments have been identified in 40 to 60% of mesothelioma samples [28] [29], but the copy
numbers were exceedingly low (less than one per cell) [29]. Furthermore, there is no current
treatment for SV40 infection.
2.3.3. Irradiation
Irradiation causes cancer and mesothelioma is no exception, Thorotrast is an alpha-emitting
thorium dioxide radiocontrast used between 1930s and 1950s. It has a physical half-life of
1010 years and a biological half-life of several hundred years, and so it is retained lifelong,
constantly exposing tissue including mesothelium to irradiation. Thorotrast is associated with
many malignancies including mesothelioma [30]. Patients with lymphoma who underwent
mantle radiotherapy represent another cohort with irradiation to the pleura. They also have a
higher risk of mesothelioma compared to population with similar levels of asbestos exposure
[31] [32].
3. Pathogenesis and biology
3.1. How asbestos causes cancer
Since most mesothelioma is associated with asbestos exposure, a lot of research has focused
on how this inorganic fibre causes cancer. The physical properties of asbestos are more
important for its carcinogenicity than its chemical composition. Many studies have confirmed
that long (≥8 μm), thin (≤0.25 μm) fibres are most strongly associated with mesothelioma. Fibres
of that size have aerodynamic features that are fine enough to allow them on the one hand to
be deposited beyond the ciliated airways where they escape mechanical clearance, and on the
other, large enough to frustrate phagocytosis by macrophages. Having been deposited, they
migrate through still poorly understood pathways to the parietal pleura where they promote
oncogenesis on the mesothelium. The chemical properties of the fibre are important insofar as
they determine the biopersistence of the fibre. Chrysotile fibres, for example, are weak and
fracture easily into shorter fibres which are easier to clear. Their apparent weak association
with mesothelioma has been attributed to the fibre’s lower biopersistence [33].
Asbestos is specifically cytotoxic to mesothelial cells in culture but not to fibroblasts [34], [35],
therefore other processes must be involved in vivo to prevent cell death, promote cell survival
and drive malignant transformation. The most widely accepted hypothesis invokes a chronic
and genotoxic inflammatory response which over time drives tumourigenesis. As the long
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fibres become deposited and transported to the parietal pleura, they are progressively taken
up by macrophages. However, because of their sheer size and biopersistence, they could not
be cleared effectively, markedly lengthening their dwell time at the mesothelium compared
to other particulates. Furthermore, macrophages are unable to engulf the entirety of these large
fibres. Such frustrated phagocytosis is a potent stimulation of the macrophage’s inflammatory
response which results in respiratory bursts and secretion of toxic metabolites such as reactive
oxygen species, growth factors and cytokines. The asbestos fibres have also themselves been
implicated in carcinogenesis through direct interference with the mitotic apparatus, and direct
generation of free radicals through its interaction with mobilisable iron on the fibre surface
[36]. Over a long period of time, it could be envisaged the unrelenting exposure to these
mutagens and growth signals could drive neoplastic transformation.
3.2. Molecular pathogenesis
A central player which promotes mesothelial transformation is believed to be tumour necrosis
factor-alpha (TNF-α). Asbestos stimulates both macrophages and human mesothelial cells to
express TNF-α. TNF-α has been shown to promote mesothelial cell survival in the face of
asbestos exposure in vitro, and the effect appears to be mediated through Nuclear Factor
Kappa-light-chain-enhancer of Activated B Cells (NF-κB) [35]. NF-κB activation results in
release of a p16 subunit which translocates to the nucleus to induce expression of antiapoptotic
genes. Meanwhile, activated macrophages also secrete a host of other cytokines and growth
factors including interleukins, vascular endothelial growth factor (VEGF) and hepatocyte
growth factor (HGF), as well as reactive oxygen and nitrogen species which directly causes
DNA and chromosomal damage. Together, this sustained insult of mutagens and growth
stimulators causes the first genetic alterations behind malignant mesothelioma.
Whilst most cancers have inactivation of the p53 and pRb tumour suppressor genes, mutation
of these genes in mesothelioma is surprisingly rare [37] [38]. In contrast, over 70% of meso‐
theliomas have deletions of 9p21 and about 40% mesothelioma have loss of heterozygosity at
the 22q12 locus [39] [40] [41] [42] [43]. 9p21 contains the INKa/ARF locus which encodes two
proteins p16INK4a and p14ARF alternatively spliced from the same mRNA. Functionally,
p14ARF stabilises p53 whilst p16INK4a inhibits the inactivation of pRb, thereby restricting
progression through the cell cycle G1 checkpoint. Thus, mutations in the INKa/ARF locus
effectively lead to loss of both tumour suppressor pathways. Positional cloning also identified
the neurofibromatosis NF2 gene within the 22q12 locus, which encodes for the protein merlin.
Merlin integrates signals from various adhesion molecules and cytoskeletal components and
promotes cell adhesion, establishes apical polarity and mediates contact inhibition. It also has
the capacity to migrate to the nucleus to modulate gene expression.
The precise mechanism of NF2 tumour suppression remains unclear [44] but it is likely to have
a salient role. Whilst only 40% mesothelioma have truncations of NF2 or merlin, in the
remaining cases, merlin is functionally inactivated through increased phosphorylation at
Ser518 [45] and changes in microRNA expression [46]. Simultaneous loss of both INKa/ARF
and NF2 appears to be important in the pathogenesis of mesothelioma. In experimental models
of asbestos-induced mesothelioma, loss of the remaining NF2 allele is accompanied by the
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concomitant loss of INKa/ARF [47]. Indeed functionally, loss of INKa/ARF appears to be
permissive for NF2 tumourigenesis [48]. Thus, the evidence points to mutations in INKa/ARF
and NF2/merlin as driver mutations central to the pathogenesis of mesothelioma. As a result
of the genetic instability conferred by these tumour suppressor gene mutations, a large number
of genetic lesions appear causing dysregulation of growth factor expression and signalling,
angiogenesis and apoptosis, conferring on the cell the phenotype of malignancy.
4. Diagnosis
Pleural diseases are common and the causes are diverse, but there is also considerable overlap
in the clinical manifestatations of these conditions. Because of this, MPM is notoriously difficult
to diagnose, both radiologically and pathologically.
4.1. Radiology
Radiologically, pleural malignancy is often suspected on clinical history and an abnormal
chest  radiograph showing pleural  effusion or thickening.  Computed tomography can be
helpful in distinguishing malignant from benign pleural processes [49]. Whilst direct invasion
of  surrounding  structures  is  diagnostic  of  malignancy,  mediastinal  pleural  thickening,
nodules in the pleura and thickness >1cm predict malignancy with a sensitivity of 40-70%
and specificity of 64-96%. In differentiating mesothelioma from secondary pleural malignan‐
cies,  mediastinal  pleural  involvement  and  rind-like  encasement  of  the  lung  shows  a
sensitivity/specificity of 85%/67% and 70%/85% respectively. Magnetic resonance imaging
(MRI) has a similar performance to CT at distinguishing benign from malignant processes
on the basis of morphology, but signal intensity is a useful additional feature which improves
the ability to differentiate between the two [50] [51]. PET-CT is less helpful for the differen‐
tiation of benign from malignant pleural diseases and is more valuable in staging than in
diagnosis [52]. Interpretation is confounded by inflammatory and infective pleural condi‐
tions  and  recent  talc  pleurodesis  [53]  [54].  Nevertheless,  none  of  these  modalities  are
absolutely  specific  so,  irrespective  of  radiological  findings,  diagnosis  of  mesothelioma
requires pathological confirmation.
4.2. Obtaining tissue for diagnosis
The mesothelium is a flattened layer of pluripotent mesodermal-derived epithelial cells on the
surface of the pleura and mesothelioma can be morphologically diverse. Two main issues face
the pathologist trying to establish a diagnosis of mesothelioma. Firstly, mesothelial prolifera‐
tion is common in benign conditions, and differentiating benign from malignant mesothelial
proliferation can be very difficult with many benign processes showing atypical features and
mimicking invasion. Secondly, of the malignant pathologies affecting the mesothelium,
secondary malignancies are by far the most common and mesothelioma is rare. Determining
that a pleural malignancy is primary can also be very difficult.
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The quality of tissue available to the pathologist greatly influences the ability to make a
diagnosis. Fluid from a pleural effusion is helpful at narrowing the differential diagnosis but
it has poor sensitivity (about 50-60%) for the diagnosis of malignancy, and in most studies the
negative predictive value is around 70% [55]. However, a diagnosis may be more forthcoming
when aspiration cytology is repeated [56]. For the specific diagnosis of mesothelioma, cytology
has an overall sensitivity of about 30-50%, and is almost useless at diagnosing sarcomatoid
mesothelioma (20% sensitivity) [57].
Tissue for histopathology can be obtained by percutaneous or thoracoscopic means. Of the
percutaneous methods, the Abram’s needle has the highest yield, but is only similar to
cytological diagnosis [58] [59]. Although pneumothorax can be expected in 15% of patients,
few require intervention and the overall complication rate is low in safe hands [60] [61]. The
addition of image guidance to target areas with >5mm pleural thickening significantly
improves the diagnostic yield to >80% and reduces the rate of complications [61].
Thoracoscopy allows direct visual inspection and target selection, at the same time enabling
greater amounts of tissue to be obtained, thereby improving the diagnostic yield for malig‐
nancy to about 95%. Video-assisted thoracoscopy requires a general anaesthetic and single
lung ventilation and may be less suited to frail patients, however, it offers the opportunity to
proceed to other procedures such as opening up loculations, pleurodesis or insertion of an
indwelling drain in case of trapped lung.
Thoracotomy and pleural excision remains the gold-standard for diagnosis of mesothelioma.
Whilst pleural biopsy, both open and close, have a high sensitivity for the diagnosis of
mesothelioma, the sensitivity for the determination of tissue subtype is approximately 80-86%
and is less accurate for non-epithelioid subtypes [62] [63].
4.3. Differentiating benign from malignant mesothelial proliferation
The separation of benign from malignant mesothelial proliferation can be extremely difficult.
Most processes that affect the pleural space, from pneumothorax to thoracic surgery, pulmo‐
nary diseases to systemic diseases cause a degree of pleuritis with a degree of reactive
mesothelial hyperplasia. This hyperplasia can be accompanied by quite florid cytological
atypia, sometimes more florid than seen in some mesothelioma. Therefore, cytological features
of a specimen are not helpful in the diagnosis of malignant mesothelioma [64].
Whilst invasion necessarily implies malignancy, benign processes in the pleura can also
produce features that mimic invasion. To demonstrate invasion requires surrounding fat and
stroma within the biopsy specimen, that is a reason why the diagnostic yield is higher with
larger surgical specimens which contain the full thickness of the pleura and the deeper
surrounding tissue. To illustrate the difficulty in clinching a diagnosis, even expert members
of the US-Canadian Mesothelioma Reference Panel disagree 22% of the time on selected cases
referred to them [65] [66].
Some benign histological features can appear ominous, one such is entrapment, where
organising pleuritis within the pleural space overlying a pleural surface gives the deceptive
appearance of mesothelial invasion. This can be complicated by the concomitant appearance
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of fat-like spaces within the organising pleuritis further giving the appearance of fat invasion
[67]. Reactive proliferation of the surrounding stroma fibroblasts and spindled mesothelial
cells can resemble sarcomatoid mesothelioma, whilst dense, fibrous pleuritis with low cellular
content can resemble desmoplastic sarcomatoid mesothelioma.
Because of the difficulties differentiating benign from malignant mesothelial cells on morpho‐
logical grounds, other techniques have been developed to this end. Unfortunately, immuno‐
histochemistry is of limited value, with poor sensitivity and specificity [68], but the
identification of mutated genes may be more fruitful. The discovery that the majority of
mesothelioma has loss of 9q21 led to the recent development of fluorescence in-situ hybridi‐
sation techniques looking for homozygous deletions of the p16INK4a gene. Loss of p16 in this
assay appears to be 100% specific for mesothelioma [40] [69]. Another avenue which has found
commercial application is diagnosis through the pattern of downregulation of specific
microRNAs [70].
4.4. Differentiating MPM from other pleural malignancies
Immunohistochemistry is indispensable for the differentiation between primary pleural
mesothelioma and secondary malignancies. A number of markers for each of mesothelioma
and the carcinoma should be used to improve the diagnostic specificity. The International
Mesothelioma Interest Group (IMIG) recommends the use of at least 2 mesothelial markers
and 2 markers of the tumour under consideration, and if no diagnosis could be arrived at, an
expanded panel could be used [64]. Epithelioid mesothelioma markers include Wilms Tumour
1 (WT-1), calretinin. cytokeratin 5 or 5/6. Thyroid transcription factor-1 (TTF-1) is useful for
the differentiation of lung adenocarcinoma, whilst CYFRA 21-1, SCCA and p63 are useful
squamous cell carcinoma markers. Markers can also be selected for secondary malignancies
of other tissue origin.
4.5. Histological subtypes
Many subtypes of mesothelioma have been described, but a single tumour can harbour several
subtypes, so they are best broadly grouped into three types: epithelioid, sarcomatoid and
mixed or biphasic. The epithelioid type is the most common (60%) whilst the other two types
comprise 20% each [71]. The histological type not only determines the main differential
diagnoses, but is also a predictor of response to treatment and one of the most powerful
prognostic predictor [72] [73] [74].
5. Clinical features
The symptoms of MPM typically present insidiously with vague symptoms [75]. The charac‐
teristic symptoms are pain in half the patients, breathlessness in a third, and constitutional
symptoms in less than 10%. At the beginning, symptoms are usually ill-defined and mild, but
as the disease progresses, the initial heaviness becomes an ache and pain that interferes with
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sleep, and the breathlessness would often force the patient to stop working. Medical attention
is usually only sought after a median of 3.5 months of progressing symptoms [76].
Physical examination is helpful insofar as suggesting a pleural effusion or pleural thickening,
but is nonspecific for the diagnosis of MPM. Peripheral stigmata of pulmonary diseases such
as clubbing and hypertrophic pulmonary osteoarthropathy are not features of MPM, and
palpable lymphadenopathy is rare.
In those with large effusion, drainage may lead to rapid improvement of symptoms but a
trapped lung is also common. As the disease progresses, less fluid is produced and there is
progressively more pleural thickening, eventually the fluid disappears and the chest becomes
contracted and filled with tumour. Local invasion of the chest wall can result in intractable
pain and paresthesia, whilst invasion of the contralateral pleural space, pericardial space or
through the diaphragm usually herald a rapid deterioration. Distant spread is common but is
usually less symptomatic than the primary site.
The outlook for patients with mesothelioma is bad. For patients who present asymptomatically
on a chest radiograph, the median survival is 20 months with best supportive care [76], and it
is with this baseline in mind that we should evaluate noncomparative studies on new therapies.
6. Staging of mesothelioma
The purpose of staging is threefold: it allows stratification of patients by the anatomical extent
of disease into groups with similar prognosis, enables comparison of results between studies
and facilitates treatment decision-making by determining the role of specific therapies in these
subgroups. However, the staging of mesothelioma is hampered by two difficulties, firstly it
has a non-spherical and non-concentric plate-like growth pattern and secondly, there is a lack
of understanding of the natural history of mesothelioma. This is reflected in the fact there has
been six different staging systems over the last 30 years [77] [78] [79] [80] [81] [82] [83]. Only
the later systems adopted the TNM model, and most have not been independently validated.
The lack of an organ within which mesothelioma grows and the way it encroaches insidiously
onto contiguous structures make clinical staging by imaging challenging. This is particularly
the case with T-staging. The latest International Mesothelioma Interest Group (IMIG) staging
system recognises that mesothelioma starts on the parietal pleura (T1a), and the spreads onto
the visceral pleura as isolated and scattered foci (T1b), which becomes confluent (T2). These
features are not easily resolvable on imaging and require direct visualisation with thoraco‐
scopy or open surgery. Nevertheless, most tumours present at the T3 and T4 stages. Here, the
preoperative determination of invasion into the chest wall, mediastinum, diaphragm or
pericardium is crucial to the separation of potentially resectable (T3) from unresectable (T4)
tumour, but in practice this is not an exact science. The visual distinction between a contiguous
structure and an invaded structure can be a difficult call. When compared to the pathological
stage, both CT and MRI have an accuracy of only 50-60% in most categories, but MRI may be
marginally more superior in the diagnosis of diaphragmatic and chest wall invasion on account
of the signal changes in these structures [84].
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Nodal metastases portends a grave prognosis in patients with mesothelioma who underwent
resection [80] [85] and so accurate staging of nodal involvement is crucial for the selection of
patients for radical treatment and prognostication. However, several factors complicate the
assessment of nodal disease. Firstly, our knowledge of nodal staging is hampered by the fact
that bronchopulmonary nodes are not routinely sampled in radical pleurectomy-decortication,
or routinely reported in extrapleural pneumonectomy specimens. Secondly, the current IMIG
staging system adopted the lung cancer nodal classification for mesothelioma. However, early
anatomical studies has already showed that lymphatic drainage of the pleura occurs first to
the chest wall (internal mammary) and paravertebral lymph nodes, whilst there is little flow
upstream through the lung parenchyma to the N1 stations [86]. Indeed, the survival of patients
with N1 disease does not appear to be any better than those with N2 disease [87] [88] [89] whilst
the extramediastinal nodes (internal mammary, pericardial, diaphragmatic) are associated
with better prognosis [90]. Finally, within the mediastinal nodes there are differences in
outcomes: involvement of upper mediastinal nodes is associated with worse prognosis [90].
This is compatible with the hypothesis that mesothelioma starts basally and progresses
apically.
Radiologically, the nodes are frequently obscured by the pleural thickening, and there is little
correlation between nodal size and disease involvement in mesothelioma [85], so that imaging
modalities based on structural criteria perform poorly at discriminating between involved and
uninvolved nodes. CT and MRI has an accuracy of about 50% for nodal staging and so cannot
be relied on [84]. For this reason, functional imaging such as PET and PET-CT have been
investigated for their role in staging. PET alone has poor spatial resolution, but when combined
with CT, increases the specificity of the PET and the sensitivity of the CT. PET-CT is more
accurate for staging resectable disease than CT, MRI or PET, through its ability to diagnose
distant metastases [91]. For nodal staging, the accuracy for mediastinal nodal involvement in
PET-CT is about 60-66% [92] [93], therefore invasive techniques such as mediastinoscopy are
still required for accurate nodal staging given its potent impact on prognosis [90]. In practice,
in a population with a ‘resectable tumour on CT’ and mandatory mediastinoscopy, PET-CT
was able to prevent futile surgery in an additional 29% patients [92].
The current staging system has several deficiencies. Firstly, it was developed with surgical
patients in mind and requires intraoperative and pathological assessment. As a result, clinical
staging is highly inaccurate and correlates with pathological staging less than 50% of the time
[89]. Secondly, it successfully stratifies survival in only some [94] and not other surgical series
[83]. Thirdly, most patients end up belonging to stage III with little differentiation within.
Fourthly, it does not predict survival in nonsurgical patients such as those following chemo‐
therapy alone [95]. There are other prognostic factors which are more powerful at stratifying
prognosis of mesothelioma patients. Cell type is an important prognostic determinant, the
hazard ratio for death following trimodality therapy is several fold higher than nodal status
and overall stage [83] [95].
Numerous other prognostic factors have been found to be associated with survival in meso‐
thelioma. They include clinical factors such as age, performance status and asbestos burden,
laboratory indices such as haemoglobin, platelet count, white cell count and serum lactate
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dehydrogenase, and biomarkers such as mesothelin and megakaryocyte potentiating factor [96]
[95] [97]. These have been variously combined into different prognostic scores. Amongst the
various scores, different factors take on different prognostic significance in different series and
ultimately, the few consistent predictive factors are age, performance status, histology and
stage. A gene ratio based test for molecular staging using the relative expression of four genes,
namely TM4SF1, PKM2, ARHGDIA, and COBLL1, has been described and internally validated
in a prospective patient set from the same institution [98]. This test was more powerful at
predicting overall survival than either histology or lymph node involvement, and when
combined with these, was able to differentiate three subgroups with very different outcomes
[99]. Nevertheless, the test suffers the same limitation as the current staging system in its
requirement for pathological data following resection.
7. Assessment of treatment response
Many tumours grow as spherical masses and linear measurements which correlate well to
tumour volume can usually be taken on cross-section imaging for the assessment of response
to treatment. The sheet like growth pattern of MPM over many different topologically complex
surfaces meant objective measure of mesothelioma responses is difficult and subject to
significant interobserver variation, the standard criteria for response assessment may therefore
be unsuited to it.
The WHO criteria was introduced in 1979 to determine whether there was a complete response,
partial response, stable disease or disease progression [100] and was based in part on evalua‐
tion of breast cancer response by palpation. Without stipulating the assessment protocol or
measurement process, it proposed taking bidimensional measurements and obtaining the
product of the longest tumour diameter with the greatest perpendicular measurement. This
led to significant variation in the assessment method, and made comparison of reporting from
different trials difficult. The Response Evaluation Criteria In Solid Tumour (RECIST) guideline
was proposed in 2000 to try to address some of these problems [101]. It moved onto unidi‐
mensional assessment and measured changes in the longest tumour diameter on standardised
imaging protocols. However, for tumours like mesothelioma, the choices of longest tumour
diameter are many and subject to interpretation and bias. To improve on this, a modification
of the RECIST criteria for mesothelioma was proposed to assess response by summating the
perpendicular thickness of the tumour rind in two positions at three levels into a unidimen‐
sional measurement, and repeating the measurements at the same position [102]. Where
appropriate for a lesion, bidimensional assessment can still be used. Within this system, a
complete response is defined as complete disappearance of all tumour, a partial response by
at least 30% reduction in the measurement on two occasions 4 weeks apart, progressive disease
as increase in the measurement by 20% or appearance of new lesions, and stable disease as
those who fulfilled neither the partial response nor progressive disease criteria.
This system was validated and showed correlation to lung function and survival outcomes
[102]. Nevertheless, there is still significant overlap in survival between those with stable
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disease and those with partial response, even following optimisation of the cut-off criteria
for each group [103]. This has significant implications for the clinical relevance of studies
which use response as their primary outcome measure instead of survival.
8. Treatment
8.1. From single to multi-modality treatment
The results of mesothelioma treatment in the 1970s and 1980s were disappointing. Radical
surgery alone was associated with high morbidity and mortality, whilst its impact on long
term outcomes was questionable [77]. The response rate to chemotherapy was poor amongst
most agents and responses were not durable with 80% of  patients developing recurrent
disease within 2 years. Mesothelioma cells are radiosensitive in the laboratory [104], but the
use of radiotherapy to treat mesothelioma was associated with significant toxicity resulting
from the extensive volume that needs to be treated and the proximity of vital organs. The
disease burden is great from both local progression and distant metastases, but none of the
modalities when used alone were effective. In 1980, Karen Antman at the then Sidney Farber
Cancer Institute in Boston, proposed the combination of resection with radiotherapy and
systemic chemotherapy in limited disease to maximise local control and minimise distant
relapse.
Studies of surgery alone have reported that following extrapleural pneumonectomy, local
recurrence occurs in a third of patients and distant recurrence in half the patients [105] [106].
Therefore, there was room to improve local control, but systemic control should also be part
of the treatment for all patients. Early work focused on adding adjuvant chemotherapy and
postoperative radiotherapy after EPP, but compliance with early chemotherapy following lung
resection was often poor due to a prolonged postoperative recovery [107]. With this in mind,
and the discovery of significant responses from platinum doublets, the Swiss investigators
adopted a strategy of neoadjuvant chemotherapy followed by surgery and hemithoracic
radiotherapy to ensure all patients received systemic treatment [108]. They showed that
surgery after neoadjuvant chemotherapy was safe and outcomes were at least comparable if
not improved. With this strategy, compliance with chemotherapy was near 100% and overall
compliance with all three treatment modalities was 60-70% [109].
Since then, each of the therapeutic modalities have undergone refinement and a number of
groups reported improved outcomes in selected patients undergoing multimodality treatment
when compared to historical results. This has led to a number of randomised trials designed
to tease out the role of various components of multimodality treatment.
In this section we will review the current state of knowledge on the treatment of mesothelioma.
The role and nuances of surgery will be covered in another chapter, and here we will focus on
radiation therapy and systemic treatment. We will review the roles of these treatments in
palliation and as part of multimodality therapy with radical intent.
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8.2. Symptom palliation
The symptoms of mesothelioma are severe and debilitating, leaving many patients miserable
for their remaining time. In particular, the severity of pain and breathlessness exceeds that in
non-small cell lung cancer patients [110].
Early on in the disease, breathlessness is due to pleural effusion compressing the lung and can
be managed effectively by drainage. If the lung reexpands following drainage, pleurodesis can
prevent reaccumulation. Most studies concern the management of malignant pleural effusions
in general which include some cases of mesothelioma. Randomised trials for the use of
sclerosant (drainage alone vs drainage with sclerosant), between different sclerosants and
between techniques (bedside vs thoracoscopic) for malignant pleural effusions in general
favoured the use of talc pleurodesis and thoracoscopy [111] [112]. One subsequent large
randomised trial did suggest equivalence between bedside talc slurry and thoracoscopic talc
pleurodesis [113], but the frequent need to obtain tissue for diagnosis usually favours the
thoracoscopic approach. The recurrence rate following thoracoscopic pleurodesis remains
however at 20-30%.
As the disease progresses, a trapped lung develops where the visceral tumour forms a
constricting cortex over the lung preventing pleural apposition. Talc pleurodesis in such
situations risks infection from long term drainage and contamination of a fixed space. VATS
pleurectomy and decortication has been advocated as a palliative procedure which does not
aim for complete macroscopic clearance, but tries to achieve lung reexpansion. There seems
to be some short-term improvement in pain and dyspnoea [114] without detriment to survival
[115] [116]. Recruitment to the randomised trial for VATS decortication (MesoVATS) has now
closed, and the results should be available in the near future [117].
Recently, the use of long term tunnelled pleural catheters for effusions with underlying
trapped lung has shown promise with very short hospital stay, low morbidity and better
patient tolerability. It compared favourably with bedside talc slurry [118]. Even in patients
with trapped lung, long term drainage could ultimately result in pleural symphysis, and the
drain could eventually be removed in a fifth of patients [119]. Furthermore, chemotherapy can
safely continue in the presence of such drains.
As the disease progresses, the effusion disappears and is replaced by a constricting tumour
and a contracted hemithorax. Management of breathlessness at this stage is difficult. A
palliative pleurectomy could be performed to relieve the restriction on ventilation and chest
wall pain but there is significant morbidity associated with such an extensive operation. On
the other hand, self-help breathlessness management techniques and opioids can help to
relieve the sensation of dyspnoea.
Pain is also a significant symptom that could be difficult to manage. In addition to the WHO
pain ladder, radiotherapy can improve chest wall pain in 50-60% patients [120] although
unfortunately in most cases the relief is not sustained [121]. There is some suggestion that
hyperthermia may increase the response rate to radiotherapy for pain control [122]. In addition,
there is a significant neuropathic component to the pain, so early referral to a specialist pain
management team may help to improve the quality of life in the final months.
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The question of whether palliative chemotherapy has additional benefit on top of best
supportive treatment was addressed by a three-armed randomised trial [123]. This was an
important landmark - whilst there were numerous phase II trials addressing different chemo‐
therapy agents, prior to this trial there were no randomised evidence to show that chemother‐
apy was beneficial over best supportive care, and most retrospective comparisons suffered
from significant selection bias. Unfortunately, the trial experienced slow accrual and was
revised to amalgamate two chemotherapy arms, which then also closed early from falling
recruitment following the results of other randomised trials. This rendered it underpowered
to show a survival difference. The trial was also criticised for employing non-standard
chemotherapy regimens which may have led to nonsignificant results [124]. Within these
limitations, it concluded the addition of chemotherapy did not improve symptoms or quality
of life to any significant degree, in part because the few symptoms which improved were
outweighed by the significant morbidity associated with chemotherapy.
The role of chemotherapy was indirectly addressed by other studies. The MED trial rando‐
mised 43 malignant mesothelioma (M) patients with stable symptoms to early (E) chemother‐
apy or to delayed (D) chemotherapy when there was symptom progression. It found patients
who received early chemotherapy had a longer freedom from symptom progression and a
better quality of life; furthermore, despite the small number of patients, there was a trend
towards prolonged survival in the early chemotherapy group [125]. In addition to this study,
a number of comparative randomised phase III studies found benefit for one regimen over
another. Unless the control arms led to worse outcome than best supportive care, which is
unlikely, these studies indirectly showed that a benefit for chemotherapy exists. Together, they
showed that chemotherapy not only has a role in palliation as well as improving survival, but
that it should be given early rather than late, and before symptoms worsen.
8.3. Chemotherapy
MPM is a particularly aggressive condition which responds poorly to treatment and chemo‐
therapy is no exception. In the rush to make an impact, numerous studies have been carried
out and almost all agents have been tried. Yet amongst these, most are small, noncomparative
phase II studies, so attempts to draw conclusions about the efficacy of each treatment were
frustrated by heterogeneity of the populations and variations in treatment schedules, assess‐
ment of response and reporting of outcomes, not to mention selection and publication biases.
Frequently, promising outcomes in smaller trials were not replicated in larger and better
conducted trials.
8.3.1. Towards cisplatin-based chemotherapy
In general, the single agent studies have been hard pressed to obtain response rates of over
20% and complete responses were rare. Of the single agent chemotherapy trials, many agents
such as the vinca alkaloids (with the exception of vinorelbine) had no efficacy, and responders
were few for the alkylating agents [126] [127] [128] [129]. The three classes of agents which
showed some degree of response, albeit with response rates that rarely exceeded 20%, were
the anthracyclines, platinum compounds and the antimetabolites/antifolates [130]. On the
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basis of this, Berghmans and colleagues carried out a metaanalysis, grouping studies into four
subgroups: those which contained cisplatin without doxorubicin, doxorubicin without
cisplatin, both doxorubicin and cisplatin and those that contained neither agents [131]. The
composite response rate was highest for the two groups that contained cisplatin, with a higher
response rate in the group that contained also doxorubicin (28.5%). On the other hand,
doxorubicin alone (11.3%) was not better than trials which contained neither cisplatin nor
doxorubicin (11.6%), suggesting cisplatin was the active agent.
A more recent metaanalysis [132] found the combined intention-to-treat (ITT) response rate
for phase II single agent trials was indeed highest for cisplatin (20.0%) whilst almost all other
classes of drugs including the anthracyclines had a rate of <10%. When used in combination,
the non-platinum combination regimens had a slight improvement over single agents (overall
response rate of 10.4%), but still remained some way behind single-agent cisplatin. On the
other hand, certain combination therapies containing cisplatin appeared to show an improve‐
ment on single-agent cisplatin such as with anthracyclines (32.4%) and gemcitabine/irinotecan
(26.1%).
These trials seemed to suggest that cisplatin is the more potent agent, and that combination
therapy could improve on the results of single-agent cisplatin. Nevertheless, these phase II
trials were hampered by their non-comparative nature, and the use of response rate as a
surrogate outcome whilst often without reporting of survival outcomes. In fact, these respons‐
es were rarely sustained, and the link between radiological response and improved survival
is tenuous.
8.3.2. The antimetabolites
Gemcitabine is a false nucleotide antimetabolite that gets misincorporated into DNA and hence
interferes with DNA synthesis and repair. It showed broad activity against many solid and
haematological malignancies, and has been evaluated in mesothelioma. The single agent trials
were however inconsistent, with three trials showing widely differing response rates of 0%,
7% and 31% [133] [134] [135]. The overall ITT response rate was a disappointing 6.9%. There
was significant heterogeneity in patient selection, chemotherapy dose and schedule, and
response evaluation to explain some of the differences seen.
Cisplatin and gemcitabine are synergistic in the killing of neoplastic cells in vitro [136]. It is
efficacious for several malignancies including non small cell lung cancer for which it became
a standard of care prior to 2008 [137]. In a single institution phase II study from Australia,
Byrne and colleagues administered a 6-cycle regimen of cisplatin and gemcitabine to 21
patients with confirmed mesothelioma. Tumour response was assessed by what was to become
the modified RECIST criteria. There was an impressive 47.6% response rate that exceeded the
results of both drugs as single agents, and a number of patients, including non-responders,
found symptom relief [138]. This led to a multicentre phase II study of 53 patients using the
same regimen [139]. However, the overall response rate this time was only 33% with a median
duration of response of 5.4 months; the overall survival from diagnosis was a median of 17.3
months. In Europe, a phase II trial using a different dosing and scheduling regimen, obtained
a response rate of 16% for the 25 patients using the WHO criteria for assessment [140].
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In the absence of better phase III results, cisplatin and gemcitabine became widely adopted at
the turn of the millenium and was also appropriated into multimodality regimens. In a single
institution Swiss trimodality study, neoadjuvant chemotherapy with cisplatin and gemcita‐
bine gave a response rate of 32% without increasing perioperative morbidity or mortality, and
the ITT overall survival was 23 months [108]. A similar study from Memorial Sloan-Kettering
Cancer Centre with 21 patients with advanced MPM reported a response rate of 26% to
neoadjuvant cisplatin and gemcitabine. There were no postoperative mortality despite
neoadjuvant treatment. The median survival was 33.5 months for those who completed all
three modalities [141].
8.3.3. The antifolates
The other class of drugs which showed promise was the antifolate family of antimetabo‐
lites. Antifolates interfere with DNA synthesis through disrupting nucleotide synthesis, a
process which requires folate. A trial of 63 patients with unresectable mesothelioma in the
1980s treated with high dose methotrexate found a 37% response rate (albeit with a looser
definition of ‘response’) [142]. Another phase II trial of edatrexate, a drug very similar to
methotrexate but for a single carbon to nitrogen substitution and greater potency, showed a
response rate of 25% but with significant toxicity (20% early deaths) [143]. This required a
protocol amendment with the use of leucovorin rescue. Unfortunately, this alteration also
reduced the response rate.
Pemetrexed is a new generation antifolate which inhibits multiple folate-dependent processes
including thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide
formyltransferase (GARFT), all of which are involved in thymidine and purine nucleotide
synthesis. However, folate competes with pemetrexed for cellular uptake. Low folate levels
result in higher intracellular accumulation of pemetrexed and thus higher cytotoxicity.
Homocysteine levels has been found to be a marker of overall folate status and correlates
clinically with pemetrexed toxicity [144]. However, a threshold level below which homocys‐
teine levels could be considered safe could not be established. From 1999, it became a require‐
ment to supplement folic acid and vitamin B12 in studies with pemetrexed, but trials straddling
that period would include both non-supplemented and then supplemented patients.
Pemetrexed on its own showed efficacy similar to other single agents. In a multicentre phase
II trial, 64 patients with confirmed MPM received pemetrexed [145], the response rate was
14.6%. Therapy was better tolerated by the supplemented patients, who also fared better with
a response rate of 16.3% and median survival of 13.0 months. This was in contrast to 9.5% and
8.0 months in the nonsupplemented patients.
A large, international, multicentre, single-blinded phase III study comparing cisplatin and
pemetrexed with cisplatin alone was carried out between 1999 and 2001[146]. In this pivotal
study, 456 chemonaïve patients with unresectable disease or who were not surgical candidates
were randomised to receive cisplatin and pemetrexed or cisplatin alone. Of these, 8 patients
were randomised but were not able to receive treatment. At mid-trial, the protocol was
modified to include folate and vitamin B12 supplementation to all enrolled patients. Supple‐
mentation greatly reduced toxicity: comparing patients who were never supplemented with
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those who were fully supplemented, the instance of neutropenic sepsis fell from 6.3% to 0.6%,
vomiting from 34.4% to 10.7% and diarrhoea from 9.4 to 3.6%.
The trial found a significantly better response rates, time to progressive disease and survival
in the combination therapy arm. The headline response rate was a remarkable 41.3% in the
combination arm and 16.7% in the cisplation-only arm (p<0.0001), all responses were partial
responses. However, true to the difficulty of assessing response, an independent review of
imaging by the FDA confirmed only 47 of the 94 reported responses in the combination arm,
but there were nevertheless still more responses in the combination arm [147].
In the final analysis, the median survival was 12.8 months in the combination arm versus 9.0
months in the cisplatin-only arm, with a hazard ratio of 0.74 [148]. Importantly, the use of
vitamin supplementation did not appear to impact on the response rate or survival outcomes.
On the basis of an advantage on survival, and in spite of the discrepant response rate data,
pemetrexed became the first agent to be approved by the FDA for the treatment of MPM in
patients whose disease is not resectable or who are otherwise not candidates for curative
surgery [149].
A validated quality of life instrument (Lung Cancer Symptom Scale – mesothelioma) was also
administered to all patients on the trial, and the overall symptom score was significantly in
favour of the combination arm. Pain scores had worsened on the cisplatin arm but improved
on the combination arm; dyspnoea scores had also worsened on the cisplatin arm but remain
unchanged on the combination arm. The authors concluded that combination cisplatin and
pemetrexed offered both symptomatic and survival benefit [150].
The trial was notable for its scale, rigorous execution and striking findings. However, it has
also attracted a number of criticisms [151] [152]. The study was single blinded and this may
have contributed to the discrepancy in observed response rates between the investigators and
the FDA reviewers. There was concern that the control group was not the standard of care, ie.
cisplatin doublet, but was instead single agent cisplatin which was not widely used. Further‐
more, the outcome of the cisplatin-alone arm was unusually poor and this may have resulted
in the combination arm appearing more efficacious. In fact, the survival benefit only reached
borderline significance (p=0.051) suggesting the conclusion would have been very sensitive to
small differences in outcome. The low toxicity seen in the vitamin supplemented patients may
suggest that the optimal dosage of pemetrexed has not been reached, as the trial dosage was
derived from the maximum tolerated dose from phase I studies carried out without supple‐
mentation.
Whilst the evidence and the FDA approval was for nonsurgical disease, on the basis of the
survival benefits of the Vogelzang trial, several phase II studies of trimodality treatment
adopted cisplatin and pemetrexed as their neoadjuvant chemotherapy from 2003. Krug and
colleagues reported a multicentre phase II trial of 77 patients with cT1-3,N0-2,M0 histologically
confirmed MPM undergoing trimodality therapy with this combination [153]. 64 patients
(81.3%) were able to complete 4 cycles of chemotherapy. The radiological response rate with
this regimen was 32.4%, of which 3 had pathological complete response at extrapleural
pneumonectomy. The ITT median survival was 16.8 months, and for the 52% who completed
Malignant Pleural Mesothelioma and the Role of Non–Operative Therapies
http://dx.doi.org/10.5772/55722
145
all three modalities, the median survival was 29.1 months. In a similar vein, a multicentre
European Organisation for Research and Treatment of Cancer (EORTC) trial in 2005-2007
recruited 58 patients with earlier stage (cT1-3,N0-1,M0) histologically-confirmed MPM for 3
cycles of cisplatin and pemetrexed followed by EPP and radical radiotherapy [154]. The
radiological response after chemotherapy was a remarkable 43.9% (24.6% complete response
and 19.3% partial response). The ITT median survival was 18.4 months. 37 patients completed
all 3 modalities and their median survival was about estimated at 33 months, although the
median was barely reached within the follow-up period and so does not allow a confident
estimate.
Another new generation antifolate which has been tested in a randomised phase III setting in
MPM is raltitrexed. Unlike pemetrexed, raltitrexed is a selective inhibitor of only one folic
enzyme - thymidylate synthase. In a phase II study, single agent raltitrexed gave a response
rate of 20.8% with only mild toxicity, without requiring vitamin supplementation [155]. This
led to a multicentre randomised phase III study of cisplatin/ raltitrexed against cisplatin alone
in patients with MPM not amenable to surgical resection [156]. 250 patients were randomised
between the two groups. The radiological response rates were 14% for the cisplatin-only group
and 24% for combination cisplatin-raltitrexed. There was a borderline significant increase in
median survival for the combination chemotherapy arm (8.8 months vs 11.4 months, p=0.048).
The study also assessed quality-of-life but did not find difference in the measures between the
two arms.
Aside from the scale of the trials, the magnitude of benefits seen in the pemetrexed and
raltitrexed randomised trials were very similar. An economic analysis recently found ralti‐
trexed/cisplatin to be much more cost effective than pemetrexed/cisplatin combination
chemotherapy [157]. Raltitrexed however, is not available in the US, and so the standard of
care there remains cisplatin with pemetrexed or gemcitabine [124].
8.3.4. Second-line chemotherapy
The response rate for existing chemotherapy is poor and many patients have disease progres‐
sion during first line therapy. Even for those who respond, the improvement is not durable.
This relentless progression inevitably leads to a question of second line chemotherapy. The
evidence for second-line therapy is however, limited, and many studies are confounded by
rampant immortal time bias – that only patients who can survive to and are fit enough to
receive second-line chemotherapy will receive it, so that treatment benefits will be arbitrarily
overestimated.
For pemetrexed-naïve patients, both pemetrexed and non-pemetrexed-containing regimens
have been used. There is little difference between the two and the outcomes were generally
poor with a median time to progression of several months. Janne et al. reported on the
outcomes of the extended access program for pemetrexed on 153 pemetrexed-naïve patients
[158]. Some patients received single-agent pemetrexed, and others combination cisplatin and
pemetrexed. The response rate and median survival was 32.5% and 7.6 months for combination
therapy and 5.5% and 4.1 months for single agent therapy. There is an element of selection bias
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as patients who were older, have poorer performance status were more likely to receive only
single agent therapy. They were also more likely to receive fewer chemotherapy cycles.
A multicentre phase III randomised trial also addressed the benefits of pemetrexed alone as
second line chemotherapy versus best supportive care in pemetrexed-naïve patients. 243
patients were randomised, but 60% patients died or progressed on the trial treatment. The
response rate was 18.7% with pemetrexed and 1.7% without, and progression free survival
and time to progression were all in favour of pemetrexed. However, there was no difference
in overall survival observed which may relate the large number of patients on the best
supportive care arm who went onto receive early post-discontinuation therapy including
pemetrexed. Quality of life was difficult to assess because of the rapid rate of attrition of these
patients.
For pemetrexed-pretreated patients, both pemetrexed-containing and non-pemetrexed-
containing regimens have been reported in noncomparative studies. For non-pemetrexed
containing regimens, the response rates were reported as <10% and the time to progression
was 2-3 months [159] [160]. Pemetrexed retreatment have also been investigated in pretreated
patients. In one Italian institutional series, 31 pretreated patients were retreated at disease
progression. There was a 19% response rate and a progression free survival of 3.8 months.
They also noted that patients who had a longer progression free survival after first line
chemotherapy also derived a longer progression free survival after second line retreatment
[161], so that the ability to respond to the drug is not lost after first line treatment. In a larger
multicentre retrospective observational study, the same authors reviewed 120 pemetrexed
pretreated patients of which 42 were retreated with a pemetrexed regimen and 78 with a non-
pemetrexed regimen. Those who received the pemetrexed regimen had a higher disease-
control rate, and those rechallenged with platinum/pemetrexed combination therapy had a
significantly longer progression free and overall survival than those receiving monotherapy
(HR 0.11) [162].
However, the results of second line therapy remain poor and there is no standard therapy, this
has made it a platform to test new agents. Many of the new targeted therapy drugs have been
investigated as part of second line therapy, but this stage of the disease also places extraordi‐
nary demands on a new agent to prove a therapeutic value, and a negative trial on this platform
risks writing off an effective agent.
8.4. Targeted therapy
In addition to the classical and largely indiscriminant cytotoxic chemotherapy, the landscape
of oncology has recently been transformed with the arrival of targeted agents which target the
many molecular alterations identified on the malignant cells. The successes of these agents in
other malignancies have also led to them being tested in mesothelioma. There are many such
agents, some of which have been or are investigated for mesothelioma. In this section we will
outline the main targets, but the list is by no means exhaustive. The prevailing theme, never‐
theless, is that the agents tested to date have not been successful.
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8.4.1. Vascular Endothelial Growth Factor (VEGF)
Angiogenesis is crucial for tumour growth and mesothelioma is no exception. Indeed,
angiogenesis is itself a poor prognostic factor for mesothelioma [163]. VEGF is not only a
paracrine growth factor for blood vessels but also an autocrine signal for mesothelioma cells
which expresses the VEGF receptors (VEGFR) -1, -2 and -3 [164]. A number of angiogenesis
inhibitors are now available, and some has demonstrated effectiveness against malignancies
such as colorectal cancer, non-small cell lung cancer (NSCLC) and multiple myeloma.
A number of anti-VEGF agents have been tested in mesothelioma but the results have been
disappointing. Bevacizumab (Avastin) is a humanised anti-VEGF-A antibody which has
showed effectiveness in metastatic colorectal cancer and NSCLC. In a phase II trial of patients
with mesothelioma not amenable to curative intent surgery, they were randomised to cisplatin/
gemcitabine with either bevazicumab or placebo. There was no difference in progression free
or overall survival [165]. In a similar vein, the addition of bevazicumab to cisplatin and
pemetrexed in a noncomparative trial did not result in improvements in response rates or
survival compared to historical results [166]. A randomised trial of pemetrexed-cisplatin with
or without bevacizumab is currently ongoing in Europe (MAPS trial).
Thalidomide has been resurrected in the 1990s when it was shown to be a powerful antian‐
giogenic agent. Clinically, it has showed effectiveness in multiple myeloma. In a dose escala‐
tion study, it was given to 40 patients with MPM irrespective of previous treatment [167].
Response was not formally reported, but only 27.5% patients were free from progression at 6
months.
Many other agents targeting the angiogenesis pathways such as sunitinib, vatalanib, sorafenib
and NGR-hTNF have been tested in MPM alone or in addition to a cisplatin doublet, however,
they mostly showed no or only very modest activity against MPM [168] [169] [170] [171].
8.4.2. Epidermal Growth Factor Signalling
EGF receptors (EGFR) is overexpressed in MPM. The tyrosine kinase inhibitors targeting
EGFR, such as erlotinib and gefitinib, have been so successful in various types of cancer they
too have been tested in MPM. Unfortunately, in phase II trials, these two agents did not show
any significant activity against MPM: in both erlotonib trials, no objective response was
observed [172] [173] whilst the gefitinib trial only showed a 4% response rate [174].
8.4.3. Histone deactylase inhibitors
Acetylation of histones is an important mechanism of epigenetic regulation of gene expression:
acetylation frees the DNA from histones and increases gene expression, at the same time
promoting cell cycle arrest or apoptosis. Histone deacetylase (HDAC) inhibitors have been
developed and investigated in MPM. In the largest randomised trial in MPM to date, 660
patients pretreated were randomised to vorinostat, (a HDAC inhibitor) or placebo. The results
were reported at the European Multidisciplinary Cancer Congress in September 2011. The
triallists reported that vorinostat did not improve the response rate or overall survival
compared to placebo [175].
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8.4.4. NF-κB pathway
The NF-κB pathway is important in the pathogenesis of mesothelioma. Two agents that target
the pathway have been investigated in mesothelioma. Bortezomib, a proteasome inhibitor
which induces apoptosis in mesothelioma cells is currently studied in several trials [176]. In a
phase II trial of monotherapy bortezomib, the response rate was 4.8%, and the majority of
patients had disease progression on treatment within the first two cycles [177]. Ranpirnase is
a ribonuclease found in the Northern Leopard Frog oocyte. It is a tRNase that also prevents
NF-κB nuclear translocation. In a large phase II study of single-agent ranpirnase which
included patients who previously did not respond to chemotherapy, the response rate was 5%
and the ITT median survival was 6 months [178]. In a phase III randomised trial of doxorubicin
with or without ranpirnase for both chemonaïve and pretreated patients, there was no
difference in ITT overall survival. However, a survival benefit could be seen in the preplanned
subgroup analysis of the pretreated subgroup [179].
9. Radiotherapy
Radiotherapy has been studied in three roles for the management of mesothelioma: the
palliation of symptoms, prevention of tract site metastases and with radical intent to improve
survival alone or as part of multimodality treatment. The first of these was covered earlier and
we will focus our discussion here on the other two roles.
9.1. Prophylactic irradiation
Mesothelioma has been known to seed along interventional tracts to form painful subcutane‐
ous nodules and radiotherapy is commonly used in the prevention of such metastases. In
general, the more invasive the procedure, the higher the likelihood is of getting tract metastases
[180]. The carte blanche to give prophylactic irradiation came from a randomised trial in 1995
[181]. Boutin et al. randomised 40 patients following thoracoscopy to local irradiation with
21Gy of 12.5-15 MeV electrons in 3 fractions within 15 days of the procedure. They found an
incidence of subcutaneous nodules of 40% in the untreated patients and 0% in the irradiated
patients. Since then, prophylactic irradiation of intervention sites has become entrenched in
guidelines [182] [183] and clinical practice [184] [185].
Two subsequent randomised trials found an incidence of subcutaneous nodules of only about
10% of patients, and that prophylactic irradiation offered no protection against the develop‐
ment of these nodules [186] [187]. The interpretation of these results was confounded by
different radiotherapy techniques in these trials [188]. Bydder et al. employed a single fraction
of 10Gy of 9MeV electrons delivered up to 15 days following intervention, and O’Rourke
employed 21Gy in 3 fractions of 9-12 MeV electrons up to 21 days following intervention.
Furthermore, all three trials were underpowered, and in none of them was histological
confirmation of subcutaneous nodules obtained.
Further questions which confuse the issue for prophylactic irradiation included the degree
to which these nodules are symptomatic - reports varied between 25% and 75% [187] [189],
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and to what degree these nodules impact on the quality of life of patients. To illustrate the
confusion and debate  surrounding the use of  prophylactic  irradiation,  we need look no
further  than the evidence-based guidelines.  The latest  British  Thoracic  Society  guideline
continue  to  recommend  prophylactic  irradiation  [190],  whilst  the  European  Society  of
Medical Oncology and the European Respiratory Society were not able to recommend it
[191, 192]. In the penumbra of all this equipoise, a new randomised trial is being conduct‐
ed to assess the role of prophylactic irradiation in the modern era of chemotherapy, in an
adequately powered multicentre study [193].
9.2. Radical radiotherapy
Radiotherapy has been used both alone and as part of trimodality therapy in the radical
treatment of MPM. A number of trials in the 1980’s examined the use of radiotherapy alone
with radical intent and found no survival benefit [194]. The use of radiotherapy for mesothe‐
lioma is complicated by the extensive field which it is required to covered, but at the same time
juxtaposition of vital structures such as lung, oesophagus, spine, heart, liver and kidneys which
limits the dose that can be delivered. Following irradiation of the hemithorax for mesothelio‐
ma, the loss of lung function is complete and equivalent to a pneumonectomy [195]. There is
a real risk of treatment-related deaths, reaching 2 out of 12 in one retrospective series [196].
Because of this, it is felt radical radiotherapy should be delivered only after extrapleural
pneumonectomy, to avoid the morbidity and mortality associated with life-threatening
toxicity to the in-field ipsilateral lung.
The local relapse rate following surgery alone is 70-80% [105], and the focus of radiotherapy
has shifted over the years to improving local control within the model of multimodality
treatment. However, the rate of local recurrence from single modality radical treatment 53%
[197], 35% [198] and 11% [199]. There is a suggestion of a dose-response relationship between
radiation dosage and local recurrence but this has not yet been established [199] [200]. Beyond
these observational series there is no randomised evidence yet to support or refute the use of
postoperative radiotherapy. A multicentre randomised trial for radiotherapy within trimo‐
dality therapy is currently recruiting, but the trial will reach completion only in late 2017 [201].
At present, it is common to include postoperative hemithoracic irradiation to 54Gy within
trimodality therapy.
With the tumour abutting a number of radiosensitive vital structures, there has been great
interest in the use of intensity-modulated radiotherapy (IMRT) to deliver radiation in a field
which conforms much more tightly to the target volume, in an effort to improve delivery to
the tumour whilst reducing bystander irradiation. It is much more complex to deliver and
requires significantly longer planning and treatment times. Whilst there is a growing body of
evidence in support of the benefits of IMRT in various cancers, its use in mesothelioma appears
to be harmful. In a series from Boston, fatal pneumonitis in the remaining lung occurred in 6
of 13 patients [202], whilst in MD Anderson, 23 of 63 patients died within 6 months of IMRT,
of which 6 were from pulmonary causes [203]. The factor which predicted pulmonary
complications appeared to be V20 (volume of lung receiving over 20Gy irradiation) [204]. At
the same time, however, the locoregional failure rate remained at 13% [203]. Several subse‐
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quent series together corroborated the findings of a relationship between pulmonary compli‐
cations and V20 [205] [206] [207]. As it stands, there is no evidence for additional benefit from
IMRT, whilst there are significant concerns about harm. IMRT has not replaced conventional
radiotherapy and its use should be confined to carefully monitored clinical trials.
Historically, EPP has been reserved for patients who are fit to undergo pneumonectomy, whilst
patients who are less fit and/or have unresectable disease are often offered radical pleurecto‐
my/decortication (P/D). However, despite this strategy, patients who underwent EPP not only
have a survival advantage over those who underwent P/D, but actually had more morbidity,
mortality and worse survival [208]. In recent years, the enthusiasm for EPP has waned and
many surgeons has shifted to offering the less morbid P/D, to the extent that the proposed
MARS2 trial intends to abandon EPP and instead randomise patients between radical P/D and
no surgery [209].
The implication this has on delivering radiotherapy within multimodality therapy is signifi‐
cant. Whilst local control becomes even more pertinent, the risk of radiotherapy is also higher
because of toxicity to the unresected lung. With the poor results of single modality radical
radiotherapy, there is little experience of radiotherapy after pleurectomy-decortication. Some
groups have delivered prophylactic radiotherapy to the surgical wounds with occasional boost
radiation to at-risk areas, and therefore although described as trimodality therapy, these
studies did not reflect the radical doses resembling that after EPP [210].
When higher dose external-beam radiation was used after pleurectomy-decortication, there
was significant treatment-related mortality and morbidity. Likewise, the addition of intrao‐
perative brachytherapy to the pleural space was associated with worse, not better survival.
Nevertheless, there was some suggestion that delivery of >40 Gys was associated with better
outcome although there is inevitably selection and immortal time bias [211]. There has been
interest therefore in the use of IMRT after pleurectomy-decortication to improve delivery of
therapeutic doses to disease area whilst keeping normal tissue irradiation to a minimum.
Planning is challenging, and for MPM requires over 20 planning cycles. A phase I study found
IMRT up to 50Gy was feasible but severe pneumonitis occurred in 20% patients. The median
survival of 26 months after receiving all three modalities was comparable to the results after
trimodality treatment with EPP [212].
10. Conclusion
In conclusion, MPM is an aggressive malignancy which presents insidiously, is difficult to
diagnose and is resistant to most standard treatments. There have been a lot of developments
over the years but the prognosis remains bleak. A number of ongoing current trials are looking
to refine the treatment of this cancer, but it will probably take a quantum leap in thinking to
really make a dent in the outcomes.
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